Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + amlodipine is a combination therapy consisting of atorvastatin, an HMG-CoA reductase inhibitor (statin), and amlodipine, a dihydropyridine calcium channel blocker. Atorvastatin functions by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing LDL cholesterol and providing pleiotropic vascular benefits. Amlodipine acts by blocking the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, resulting in peripheral vasodilation and a reduction in blood pressure. This combination is primarily indicated for patients with comorbid hypertension and dyslipidemia. A Phase 4 study conducted at Gachon University Gil Medical Center specifically investigated the additive beneficial vascular and metabolic effects of this combination compared to monotherapy in patients with mild-to-moderate hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + amlodipine.